Considerations for Menstrual Suppression in Patients With Hematologic Malignancies

Area of Science:

• Oncology
• Hematology
• Gynecology

Background:

• Patients with hematologic malignancies undergoing chemotherapy are at increased risk of heavy vaginal bleeding.
• Thrombocytopenia, stemming from malignancy and myelosuppressive chemotherapy, exacerbates this bleeding risk.
• Heavy menstrual bleeding leads to significant morbidity in this vulnerable patient group, necessitating proactive management.

Purpose of the Study:

• To review available prophylactic menstrual suppression agents for patients with hematologic malignancies.
• To discuss the factors influencing the selection of menstrual suppression methods.
• To propose a systematic approach for choosing the optimal agent based on patient-specific characteristics.

Main Methods:

• Literature review of current evidence on menstrual suppression in hematologic malignancy patients.
• Analysis of different classes of agents: gonadotropin-releasing hormone agonists, progestin-only therapy, and combined hormonal contraception.
• Evaluation of factors influencing agent choice, including efficacy, bleeding status, contraception needs, and thrombotic risk.

Main Results:

• Menstrual suppression is a crucial component of supportive care for these patients.
• Available options include GnRH agonists, progestin-only agents, and combined hormonal contraceptives, each with distinct profiles.
• Selection criteria involve balancing efficacy, acute bleeding management, contraceptive requirements, and thrombotic risk assessment.

Conclusions:

• Appropriate selection of menstrual suppression is vital for reducing morbidity in patients with hematologic malignancies.
• A methodical, patient-centered approach is necessary to navigate the complexities of agent choice.
• Further research may refine guidelines for optimal menstrual management in this population.